Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12

March 12 (Reuters) - Eli Lilly and Co LLY.N:

• AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12

• ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12

• ELI LILLY - TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.

• ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWN

• ELI LILLY: HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ABOUT THESE FINDINGS

• ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITE

• LILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HIGH ENDOTOXIN LEVELS

• ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION, INCLUDING BY REQUESTING RECALL OF ALL COMPOUNDED TIRZEPATIDE COMBINED WITH UNTESTED ADDITIVES LIKE B12